- Home
- CHPT vs AVIR Comparison
CHPT vs AVIR Comparison
Compare CHPT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- AVIR
- Stock Information
- Founded
- CHPT 2007
- AVIR 2012
- Country
- CHPT United States
- AVIR United States
- Employees
- CHPT N/A
- AVIR N/A
- Industry
- CHPT Industrial Specialties
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- CHPT Consumer Discretionary
- AVIR Health Care
- Exchange
- CHPT Nasdaq
- AVIR Nasdaq
- Market Cap
- CHPT 256.9M
- AVIR 290.4M
- IPO Year
- CHPT N/A
- AVIR 2020
- Fundamental
- Price
- CHPT $11.08
- AVIR $3.20
- Analyst Decision
- CHPT Hold
- AVIR Hold
- Analyst Count
- CHPT 11
- AVIR 1
- Target Price
- CHPT $18.40
- AVIR $6.00
- AVG Volume (30 Days)
- CHPT 478.3K
- AVIR 452.1K
- Earning Date
- CHPT 12-03-2025
- AVIR 11-07-2025
- Dividend Yield
- CHPT N/A
- AVIR N/A
- EPS Growth
- CHPT N/A
- AVIR N/A
- EPS
- CHPT N/A
- AVIR N/A
- Revenue
- CHPT $397,731,000.00
- AVIR N/A
- Revenue This Year
- CHPT N/A
- AVIR N/A
- Revenue Next Year
- CHPT $12.63
- AVIR N/A
- P/E Ratio
- CHPT N/A
- AVIR N/A
- Revenue Growth
- CHPT N/A
- AVIR N/A
- 52 Week Low
- CHPT $8.55
- AVIR $2.46
- 52 Week High
- CHPT $30.00
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- CHPT 49.94
- AVIR 53.72
- Support Level
- CHPT $10.48
- AVIR $3.04
- Resistance Level
- CHPT $11.35
- AVIR $3.30
- Average True Range (ATR)
- CHPT 0.68
- AVIR 0.12
- MACD
- CHPT -0.15
- AVIR 0.03
- Stochastic Oscillator
- CHPT 30.10
- AVIR 71.60
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).